Detalhe da pesquisa
1.
The Nucleoside/Nucleotide Analogs Tenofovir and Emtricitabine Are Inactive against SARS-CoV-2.
Molecules
; 27(13)2022 Jun 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35807457
2.
Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical Trials.
Clin Infect Dis
; 73(8): 1440-1451, 2021 10 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33987636
3.
Heavy antiretroviral exposure and exhausted/limited antiretroviral options: predictors and clinical outcomes.
AIDS
; 38(4): 497-508, 2024 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38079588
4.
Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohorts.
Lancet HIV
; 11(5): e321-e332, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38621392
5.
Beyond Undetectable: Modeling the Clinical Benefit of Improved Antiretroviral Adherence in Persons With Human Immunodeficiency Virus With Virologic Suppression.
Open Forum Infect Dis
; 10(5): ofad230, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37213424
6.
Modelling-based prediction of clinical benefits from etravirine in the TMC125-C223 trial.
HIV Clin Trials
; 8(2): 68-76, 2007.
Artigo
em Inglês
| MEDLINE | ID: mdl-17507322
7.
Stalemate--but not checkmate. An expert takes on the challenges. Interview by Jeff Berry.
Posit Aware
; 21(2): 56-8, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-20524352
8.
Emergent HIV-1 Drug Resistance Mutations Were Not Present at Low-Frequency at Baseline in Non-Nucleoside Reverse Transcriptase Inhibitor-Treated Subjects in the STaR Study.
Viruses
; 7(12): 6360-70, 2015 Dec 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-26690199
9.
Treatment interruption; advanced HIV; new ideas: Dr. Cal Cohen interview on retrovirus conference (part 2 or 2). Interview by John S. James.
AIDS Treat News
; (390): 2-5, 2003 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-12739473
10.
Retroviruses Conference clinical news; interview with Cal Cohen, M.D. Interview by John S. James.
AIDS Treat News
; (389): 2-6, 2003 Mar 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-12712936
11.
New fixed-dose once-a-day starting regimens: interview with Cal Cohen, M.D. Interview by John S. James.
AIDS Treat News
; (405): 3-6, 2004 Sep 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-15595150
12.
Weekend treatment interruptions for certain well-controlled patients: interview with Cal Cohen, M.D. Interview by John S. James.
AIDS Treat News
; (407-408): 2-4, 2004.
Artigo
em Inglês
| MEDLINE | ID: mdl-15717379
13.
Antiretroviral treatment update from the 17th International AIDS Conference.
AIDS Read
; 18(11): 570-9, 2008 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-19062402
14.
Durable suppression possible with FOTO treatment schedule in subjects on nevirapine-based regimens.
HIV Clin Trials
; 8(4): 256, 2007.
Artigo
em Inglês
| MEDLINE | ID: mdl-17720667
15.
Codevelopment of new antiretrovirals in very treatment-experienced HIV-infected individuals.
Lancet
; 364(9439): 1036-7, 2004.
Artigo
em Inglês
| MEDLINE | ID: mdl-15380959
16.
HAART at 10: an interview with Cal Cohen.
Res Initiat Treat Action
; 11(1): 49-51, 2005.
Artigo
em Inglês
| MEDLINE | ID: mdl-16208821
17.
New fixed dose once-a-day combinations. Interview by John S. James.
IAPAC Mon
; 10(11): 414-5, 432, 2004 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-15744891
18.
Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen.
AIDS
; 22(17): 2279-89, 2008 Nov 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-18981767
19.
Issues in the design of trials comparing management strategies for heavily pretreated patients.
Curr Opin HIV AIDS
; 1(6): 476-81, 2006 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-19372849
20.
Effect of prolonged discontinuation of successful antiretroviral therapy on CD4+ T cell decline in human immunodeficiency virus-infected patients: implications for intermittent therapeutic strategies.
J Infect Dis
; 186(6): 851-4, 2002 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-12198623